Publication: Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Open/View Files
Date
2015
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Pub. Group
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Miao, J., A. V. Ling, P. V. Manthena, M. E. Gearing, M. J. Graham, R. M. Crooke, K. J. Croce, et al. 2015. “Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis.” Nature Communications 6 (1): 6498. doi:10.1038/ncomms7498. http://dx.doi.org/10.1038/ncomms7498.
Research Data
Abstract
Despite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 (Fmo3) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro, increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service